Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma

NCT01124786 is registered in ClinicalTrials.gov with Clovis Oncology, Inc. as lead sponsor.

NCT NCT01124786
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01124786 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Clovis Oncology, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2010
Completion date
June 30, 2013
Enrollment
367 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic adenocarcinoma